Clinical trials: Cancer Disease Progression
Hepatocellular Carcinoma; Targeted Therapy; Progression-free Survival
Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma
This is an open, prospective, single-arm, multi-cohort clinical study to evaluate the efficacy and safety of surufatinib alone or combined with Anti-PD-1 mAb in the treatment of advanced Hepatocellular Carcinoma
- Trial name
- NCT05282433
- Testing
- Surufatinib
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Zhongnan Hospital
Neuroblastoma, Sarcoma
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
This study will expand the types of pediatric cancers being evaluated for response to cabozantinib. The current COG study is restricted to Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, Wilms tumor, and a handful of uncommon…
- Trial name
- NCT05135975
- Testing
- Cabozantinib
- Where
- 6 sites in United States
- Volunteers
- 86 people
- Sponsor
- Nationwide Children's Hospital
Non Small Cell Lung Cancer, Small-cell Lung Cancer
DIAGNOSIS, TREATMENT AND OUTCOME OF LUNG CANCER PATIENTS
Observational, prospective clinical research, multi-center clinical research platform with the main objective to assess molecular biomarker testing, treatment and outcome of patients with NSCLC or SCLC in Turkey
- Trial name
- REGISTURK-LUNG (NCT05254119)
- Where
- 39 sites in Turkey (Türkiye)
- Volunteers
- 6,000 people
- Sponsor
- Mahmut Gumus
Non-small Cell Lung Cancer
MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib
Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations in patients with non-small-cell lung cancer.
- Trial name
- MELROSE (NCT03865511)
- Testing
- TAGRISSO® 80mg (Osimertinib), Tumor biopsies, ctDNA analysis
- Where
- 17 sites in France
- Volunteers
- 150 people
- Sponsor
- Nantes University Hospital
Lung Cancer
Feasibility of re Biopsies at Progression
Feasibility of new biological and histological samples at progression in patients with advanced or metastatic Non Small Cell Lung Cancer (NSCLC). A recent paper from Professor Sequist and coll.
- Trial name
- GFPC-REBIOP (NCT02086071)
- Testing
- re biopsy
- Where
- 9 sites in France
- Volunteers
- 100 people
- Sponsor
- Groupe Francais De Pneumo-Cancerologie
Breast Cancer
Construction and Validation of an Assessment Model of PCR After NAT on Breast Cancer Patients With AI Technology
Breast cancer is a major cause of survival for women worldwide. Neoadjuvant therapy as an important treatment for locally advanced breast cancer has had many positive effects for breast cancer patients.
- Trial name
- NCT05441098
- Testing
- Neoadjuvant therapy
- Where
- China
- Volunteers
- 1,821 people
- Sponsor
- Chinese Academy of Medical Sciences
Prostate Cancer Metastatic Disease, PET / CT
The Prognostic Value of PET/CT for Tumor Progression in Patients With Metastatic Hormone-sensitive Prostate Cancer
Investigators retrospectively collected data from consecutive patients treated at the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, from October 2020 to March 2024.
- Trial name
- NCT06915714
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Sun Yat-sen University
Pancreatic Cancer
Role of Exosomes in Pancreatic Cancer Progression
The present pilot study is set up with the objective of identifying circulating markers in the biological fluids (blood and urine) of subjects with pancreatic carcinoma and their association with disease stage, to evaluate their…
- Trial name
- NCT06777030
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Gastric Cancer
Study Maintenance Regorafenib vs Placebo, no Progression Patients After I Line Chemotherapy Metastatic Gastric Cancer
Randomized, double-blind, placebo-controlled, multicenter Phase-II study. Approximately 120 subjects with CR/PR/SD after platinum compounds and fluoropyrimidines based regimens: up to 6 cycles of cisplatin and 5-fluorouracil or…
- Trial name
- a-MANTRA (NCT03627728)
- Testing
- Regorafenib
- Where
- Italy
- Volunteers
- 67 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
Ovarian Cancer
AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer
This randomized, open-label, 2-arm study will evaluate the efficacy and safety of Avastin added to chemotherapy versus chemotherapy alone in patients with epithelial ovarian, fallopian tube or primary peritoneal cancer with…
- Trial name
- NCT00976911
- Testing
- Bevacizumab, liposomal doxorubicin, paclitaxel
- Where
- 117 sites in Belgium, Bosnia and Herzegovina and 12 more
- Volunteers
- 361 people
- Sponsor
- Hoffmann-La Roche
Non Small Cell Lung Cancer NSCLC
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy + Standard of care (SoC) chemotherapy or durvalumab monotherapy + SoC…
- Trial name
- POSEIDON (NCT03164616)
- Testing
- Durvalumab, Tremelimumab, Abraxane + carboplatin
- Where
- 175 sites in United States, Brazil and 17 more
- Volunteers
- 1,186 people
- Sponsor
- AstraZeneca
Metastatic Colorectal Cancer
Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer
This is a phase II, randomized, multi-center, open-label, parallel-group study to evaluate the progression-free survival during maintenance therapy. Eligible patients will be treated within a 12-week induction therapy.
- Trial name
- PanaMa (NCT01991873)
- Testing
- Maintenance Chemotherapy, Panitumumab (Within maintenance phase), mFOLFOX6 (Within re-induction phase)
- Where
- 2 sites in Germany
- Volunteers
- 387 people
- Sponsor
- AIO-Studien-gGmbH
Prostate Cancer
HDR Brachytherapy as Monotherapy for Low and Intermediate Risk Prostate Cancer
The purpose of this study is to evaluate High-dose rate (HDR) brachytherapy (1 vs 2 fractions on single implant) as monotherapy for the treatment of low risk and intermediate risk prostate cancer
- Trial name
- BRP2 (NCT03424694)
- Testing
- HDR brachytherapy as monotherapy
- Where
- Canada
- Volunteers
- 199 people
- Sponsor
- CR-CSSS Champlain-Charles-Le Moyne
Malignant Pleural Mesothelioma, Advanced, Malignant Pleural Mesothelioma, Unresectable
A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma
This is a national, single arm, phase II trial in patients with diagnosis of unresectable or advanced malignant pleural mesothelioma who experienced progression after platinum-based chemotherapy.
- Trial name
- NCT03786419
- Testing
- Atezolizumab
- Where
- Mexico
- Sponsor
- Health Pharma Professional Research
Breast Cancer Invasive, Metastatic Cancer
COntinue the SaMe Systemic Therapy After Local Ablative Therapy for Oligo Progression in Metastatic Breast Cancer - the COSMO Study
Patients with oligoprogression of metastatic breast cancer during palliative treatment that is amenable to local therapy will be included.
- Conditions
- Breast Cancer Invasive, Metastatic Cancer, Oligoprogressive
- Trial name
- COSMO (NCT05301881)
- Testing
- Surgery, Radiotherapy, Radiofrequent ablation
- Where
- 7 sites in Netherlands
- Volunteers
- 56 people
- Sponsor
- The Netherlands Cancer Institute
Myeloma
Dasatinib in Combination With Melphalan and Prednisone to Treat Relapsed and Refractory Multiple Myeloma Patients
Clinically demonstrated efficacy of Melphalan and Prednisone in MM subjects as well as the confirmed inhibitory effect of dasatinib on several tyrosine kinase receptors and pathways implicated in the pathophysiology of MM.
- Trial name
- D-MP (NCT01116128)
- Testing
- dasatinib, melphalan, prednisone
- Where
- Italy
- Volunteers
- 8 people
- Sponsor
- Fondazione EMN Italy Onlus
Lung Cancer Stage IV
Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIs
About 20%-40% of NSCLC patients develop intracranial metastases, and most clinical studies suggest that the survival of lung cancer patients will be significantly shortened once they develop intracranial metastases.
- Trial name
- NCT04519983
- Testing
- Aumolertinib Oral Tablet
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Cancer Hospital, China
Chronic Lymphocytic Leukemia (CLL)
A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).
The purpose of this open-label, single-arm study was to evaluate the impact of venetoclax on the quality of life of participants including those with with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL; a type of…
- Trial name
- VENICE II (NCT02980731)
- Testing
- Venetoclax
- Where
- 33 sites in Argentina, Australia and 8 more
- Volunteers
- 210 people
- Sponsor
- AbbVie
Endometrial Neoplasms, Neoplasm Recurrence, Local
Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma
The goal of this clinical trial is to evaluate the efficacy and safety of cadonilimab in combination with paclitaxel, cisplatin, and radiation therapy for the treatment of locally recurrent and oligometastatic endometrial…
- Conditions
- Endometrial Neoplasms, Neoplasm Recurrence, Local, Neoplasm Metastasis
- Trial name
- NCT06532539
- Testing
- Paclitaxel and Cisplatin, Cadonilimab, Radiotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shandong Cancer Hospital and Institute
Metastatic Breast Cancer
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
This trial is designed to enroll postmenopausal patients with locally advanced or metastatic, HER2- and HR+ breast cancer not amenable to curative treatment by surgery or radiotherapy, and whose disease has progressed on or after…
- Trial name
- NCT01528345
- Testing
- Dovitinib, Fulvestrant
- Where
- 67 sites in United States, Argentina and 13 more
- Volunteers
- 97 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.